Abstracts tagged "risk factors"

Abstract Number: 0705 • ACR Convergence 2022
Severity of SARS-CoV-2 Omicron Breakthrough Infections in Patients with Rheumatic Immune-mediated Inflammatory Diseases and Healthy Controls: Data from a Prospective Cohort Study
Laura Boekel¹, Yaëlle Besten¹, Femke Hooijberg¹, Rosa Wartena¹, Maurice Steenhuis², Erik Vogelzang³, Maureen Leeuw¹, Sadaf Atiqi¹, Sander Tas⁴, Willem Lems⁵, Marieke van Ham², Filip Eftimov³, Eileen Stalman³, Luuk Wieske³, Taco Kuijpers³, Alexandre Voskuyl⁶, Ronald van Vollenhoven⁷, Martijn Gerritsen¹, Charlotte Krieckaert¹, Theo Rispens², Maarten Boers⁸, Michael Nurmohamed⁹ and Gertjan Wolbink¹, ¹Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ²Sanquin Research, Amsterdam, Netherlands, ³Amsterdam UMC, location AMC, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center, location AMC, Amsterdam, Netherlands, ⁵Amsterdam Rheumatology and immunology Center, location VUMC, Amsterdam, Netherlands, ⁶Amsterdam UMC, Amsterdam, Netherlands, ⁷Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁹Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: The Omicron (B.1.1.529) variant of SARS-CoV-2 is associated with substantially lower hospitalization rates compared with previous variants of SARS-CoV-2 (i.e., Wildtype, Alpha [B.1.1.7] and…
Abstract Number: 1318 • ACR Convergence 2022
Low-Dose Prednisolone (≤5 Mg/d) Is Not Associated with Deleterious Effects on Bone Mineral Density: Baseline Findings in a Cohort of Rheumatic Disease Patients with Prior Glucocorticoid Exposure
Edgar Wiebe¹, Dörte Huscher², Desirée Schaumburg¹, Andriko Palmowski¹, Sandra Hermann¹, Thomas Buttgereit³, Robert Biesen⁴, Gerd Burmester⁵, Yannick Palmowski⁶, Maarten Boers⁷, John Stone⁸, Christian Dejaco⁹ and Frank Buttgereit¹⁰, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Institute of Biometry and Clinical Epidemiology, and Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³Department of Dermatology, Venerology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Charité University Medicine Berlin, Berlin, Germany, ⁶Spine Department, Center for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁸Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁹Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ¹⁰Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: Inflammatory rheumatic and musculoskeletal diseases (iRMD) are associated with increased systemic bone loss that is mediated by chronic inflammation, treatment with glucocorticoids (GC), and…
Abstract Number: 1764 • ACR Convergence 2022
Utilization of Electronic Health Record Data to Evaluate the Impact of Urban Environment on Risk of Systemic Lupus Erythematosus Symptoms
Janet Song¹, Noah Forrest¹, Kathleen Mittendorf², Wei-Qi Wei², Leah Kottyan³, Rosalind Ramsey-Goldman¹, Theresa Walunas¹ and Abel Kho¹, ¹Feinberg School of Medicine, Chicago, IL, ²Vanderbilt University Medical Center, Nashville, TN, ³Cincinnati Children's Hospital Medical Center, Cincinatti, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) has a complex and poorly understood etiology and is difficult to diagnose due to its varied presentation across many organ…
Abstract Number: PP20 • ACR Convergence 2022
‘It Is Due to Stress’ – But Which Type of Stress? Cumulative childhood stress is a risk factor for autoimmune disease
Melissa Allman, Michigan State University, Meridian Charter Township, MI
Background/Purpose: Trauma can have profound detrimental influences on our health and well-being. I am tangibly familiar with how trauma can impact the individual due to…
Abstract Number: 0262 • ACR Convergence 2022
Predictors of Fragility Fracture Amongst Patients with Rheumatoid Arthritis: An Observational Cohort Study
Seema Sharma¹ and Marwan Bukhari², ¹Lancaster Royal Infirmary, Lancaster, United Kingdom, ²University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is associated with reduced bone mineral density and almost one third of this population have osteoporosis leading to increased risk of…
Abstract Number: 0777 • ACR Convergence 2022
Immune Checkpoint Inhibition and Preexisting Autoimmune Disease: A Retrospective Cohort Study
Arjun Raghavan¹, Liam O'Neil¹, Carrie Ye² and Jeffrey Graham¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: The advent of immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of cancer. Patients with pre-existing autoimmune diseases (AID) were largely excluded from…
Abstract Number: 1410 • ACR Convergence 2022
Subclinical Atherosclerosis Is Not Related with Acid Uric in Rheumatoid Arthritis: Study of 1005 Patients of a Single University Hospital
Fabricio Benavides Villanueva¹, Cristina Corrales¹, Ivan Ferraz Amaro², Nuria Vegas Revenga³, Ricardo Blanco⁴, Miguel Angel Gonzalez Gay⁵ and Alfonso Corrales⁶, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³Hospital Galdakao- Usansolo, Galdakao, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, Lugo, Spain, ⁶Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Rheumatoid Arthritis (RA) and Gout are related with increased cardiovascular (CV) disease. Carotid plaques and increased carotid intima-media thickness (cIMT) are surrogate markers of…
Abstract Number: 1773 • ACR Convergence 2022
Epidemiology and Outcomes of Raynaud’s Phenomenon Hospitalizations in the US
Rashmi Dhital¹, Monica Guma², Thuthiri Lwin³, Amar Suwal⁴ and Brian Pedersen¹, ¹UC San Diego, San Diego, CA, ²UCSD, La Jolla, CA, ³University of California San Diego, San Diego, CA, ⁴Reading Hospital, Tower Health, Reading, PA
Background/Purpose: The prevalence of Raynaud's phenomenon (RP) in the general population is ~3-5%, of which 80–90% are primary. Autoimmune diseases are the most common causes…
Abstract Number: 0268 • ACR Convergence 2022
Risks of Mortality in Elderly-onset Rheumatoid Arthritis: Analysis from the TRA Clinical Electronic Registry
Ching-Tsai Lin¹, Wen-Nan Huang¹, Yi-Hsin Chen² and Yi-Ming Chen³, ¹Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ²Taichung Veterans General Hospital, Taichung, Taiwan, ³Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Patients with rheumatoid arthritis (RA) were associated with increased mortality rate. Our study aimed to investigate the risk factors associated with all causes of…
Abstract Number: 0804 • ACR Convergence 2022
Incidence and Risk Factors of Active Tuberculosis in Patients with Rheumatic Diseases Complicated with Tuberculosis Infection: A Multicenter Prospective Cohort Study
Lifan Zhang¹, yuchen liu², xiaoqing zou³, shi chen², yanan ma², huimin ma⁴, qifei cao⁴, zhengrong yang⁴, Fengchun ZHANG⁵, Yan Zhao⁵, Xiaofeng Zeng⁶ and Xiaoqing Liu¹, ¹Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China, ³Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁴Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Peking Union Medical College Hospital, Beijing, China, ⁶Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: China remains a high-burden country of both rheumatic disease (RD) and tuberculosis (TB) till today. Patients with RD are considered as a high-risk population…
Abstract Number: 1441 • ACR Convergence 2022
Prevalence of Secondary Connective Tissue Diseases and Autoantibodies Among Racial and Ethnic Groups in Systemic Lupus Erythematosus Patients in the Manhattan Lupus Surveillance Program
Brendan Denvir¹, Philip Carlucci², Jill Buyon³, H Michael Belmont⁴, Kelly Corbitt¹, Sara Sahl⁵, Jane Salmon⁶, Anca Askanase⁷, Joan Bathon⁷, Laura Geraldino-Pardilla⁸, Yousaf Ali⁹, Ellen M. Ginzler¹⁰, Chaim Putterman¹¹, Caroline Gordon¹², Hilary Parton¹³ and Peter Izmirly³, ¹New York University, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Harbor-University of California Medical Center, Los Angeles, CA, ⁶Hospital for Special Surgery, New York, NY, ⁷Columbia University Medical Center, New York, NY, ⁸Columbia University, New York, NY, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ¹¹Albert Einstein College of Medicine, Bronx, NY, ¹²Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹³New York City Department of Health and Mental Hygiene, New York, NY
Background/Purpose: Epidemiologic data of secondary connective tissue disease and autoantibody profiles among patients with systemic lupus erythematosus (SLE) remains limited for racial/ethnic populations in the…
Abstract Number: 1789 • ACR Convergence 2022
Gout in Heart Failure Patients with Left Ventricular Assist Device Therapy in a Tertiary Academic Hospital
Aakriti Arora¹, Lakshmi Jayaram², TEFERA ESHETU³ and FLORINA CONSTANTINESCU³, ¹MedStar Washington Hospital Center, Georgetown University, Washington, DC, ²McGaw Medical Center, Northwestern University, Chicago, IL, ³MedStar Washington Hospital Center, Washington, DC
Background/Purpose: Gout is one of the most common inflammatory joint diseases and is a disabling complication in patients with heart failure. Patients with gout and…
Abstract Number: 0338 • ACR Convergence 2022
Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors
Jeffrey X. Yang¹, Mehmet Hocaoglu², Jose A Meade-Aguilar¹, Alain Sanchez-Rodriguez¹, Mark Denis P Davis³, Hannah Langenfeld⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Smoking and use of estrogen-containing oral contraceptives (OCP) are SLE risk factors. Data on transitioning from cutaneous lupus erythematosus (CLE) to SLE and potential…
Abstract Number: 0828 • ACR Convergence 2022
Impact of Hospitalization on Clinical Outcomes in Patients with Connective Tissue Disease-associated Interstitial Lung Disease
Navneet Kaur¹, Xianhong Xie², Anna Korogodina³, Krystal L. Cleven⁴, Bibi Ayesha⁵ and Anand Kumthekar⁶, ¹Touro University Medical Group, Sacramento, CA, ²Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, ³Department of Medicine, Montefiore Medical Center-Wakefield/Albert Einstein College of Medicine, Bronx, NY, ⁴Division of Pulmonary Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁵Montefiore Medical Center, Tarrytown, NY, ⁶Division of Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with connective tissue disease (CTD). The aim of our study…
Abstract Number: 1449 • ACR Convergence 2022
Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study
Lifan Zhang¹, xiaoqing zou², Lantian Xie³, Jianghao Liu³, zhengrong yang⁴, qifei cao⁴, Chunlei Li⁵, Xiaochuan Sun⁵, Fengchun ZHANG⁶, Yan Zhao⁷, Xiaofeng Zeng⁸ and Xiaoqing Liu¹, ¹Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China, ⁴Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁶Peking Union Medical College Hospital, Beijing, China, ⁷Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: The burden of tuberculosis (TB) and systemic lupus erythematosus (SLE) in China are both the second largest in the world. Patients with SLE are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].